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Abstract
Background: Continuous infusion of vancomycin is increasingly preferred as an alternative to intermittent
administration in critically ill patients. Intermittent vancomycin treatment is associated with an increased
occurrence of nephrotoxicity. This study was designed to determine the incidence and risk factors of acute kidney
injury (AKI) during continuous infusion of vancomycin.
Methods: This was a retrospective, observational, two-center, cohort study in patients with microbiologically
documented Gram-positive pneumonia and/or bacteremia and normal baseline renal function. Vancomycin dose
was adjusted daily aiming at plateau concentrations of 15-25 μg/mL. AKI was defined as an increase in serum
creatinine of 0.3 mg/dL or a 1.5 to 2 times increase from baseline on at least 2 consecutive days after the initiation of
vancomycin. Primary data analysis compared patients with AKI with patients who did not develop AKI. A binary
logistic regression analysis using the forward stepwise method was used to assess the risk factors associated with AKI.
Results: A total of 129 patients were studied of whom 38 (29.5%) developed AKI. Patients with AKI had higher
body weight (77.3 ± 15 vs. 70.5 ± 15.2 kg; p = 0.02), more diabetes (79% vs. 54%; p = 0.01), and a higher
vasopressor need (87% vs. 59%; p = 0.002). Serum vancomycin levels, body weight, and SAPS 3 score were
identified as variables contributing to AKI. The incidence of AKI increased substantially when treatment duration
was prolonged (14.9 ± 9.8 vs. 9.2 ± 4.9 days; p = 0.05) and plasma levels exceeded 30 μg/mL.
Conclusions: AKI is frequently observed during continuous vancomycin infusion, particularly when conditions that
cause acute (shock) or chronic (diabetes) renal dysfunction are present and vancomycin levels above target range
are achieved. Although this study challenges the concept that continuous vancomycin infusion might alleviate the
risk of nephrotoxicity in critically ill patients, a direct relationship between vancomycin and nephrotoxicity remains
to be proven.
Background
Several reasons might explain why conventional twice-
daily dosing of vancomycin often fails to obtain microbio-
logical and clinical cure in patients with Staphylococcus
aureus (SA) pneumonia and bloodstream infections: poor
penetration in infected and/or ventilated lung tissue, a
subtle but significant increase in minimal inhibitory con-
centration (MIC) over time, also referred to as the MIC
“creep,” and the emergence of heteroresistant strains [1,2].
These observations have prompted experts to decrease
the breakpoint of vancomycin susceptibility from 4 to
2 μg/mL and to recommend targeting serum vancomycin
trough levels of 15-20 μg/mL for the treatment of methi-
cillin-resistant SA (MRSA) pneumonia [3]. However,
attempts to optimize vancomycin exposure and hence
antibacterial effectiveness by using higher loading and
maintenance doses are associated with an increased inci-
dence of nephrotoxicity [4].
Continuous infusion of vancomycin has been pro-
posed as a logistically and pharmacodynamically more
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convenient alternative to intermittent administration [5].
However, the risk of developing acute kidney injury
(AKI) during continuous vancomycin infusion remains
poorly examined, especially in the critically ill. Vanco-
mycin pharmacodynamics in this population is chal-
lenged by large variations in distribution volume during
resuscitation, enlargement of the extracellular space, and
significant fluctuations in renal clearance [6]. Intensive
care unit (ICU) patients also are exposed to a wide array
of potential nephrotoxic agents, which increases the risk
for vancomycin-associated nephrotoxicity.
Defining the incidence and risk factors of AKI asso-
ciated with continuous vancomycin infusion is important
given the availability of alternative anti-Gram-positive
agents that are believed to be less nephrotoxic. We there-
fore studied the relationship between vancomycin steady
state plateau concentrations during continuous infusion
and occurrence of AKI in ICU patients with Gram-posi-
tive bacteremia and/or pneumonia. Additionally, poten-
tial risk factors for nephrotoxicity during vancomycin
infusion were identified.
Methods
A retrospective observational cohort study was conducted
in the ICUs of two Belgian tertiary care hospitals: Univer-
sity Hospital, Vrije Universiteit Brussels; and Antwerp
University Hospital, University of Antwerp. Patients who
were hospitalized from January 1, 2008 until November
31, 2009 were included in the study if they were older
than aged 18 years, had an absolute neutrophil count ≥
1,000 cells/mm3, had a microbiologically documented
Gram-positive pneumonia and/or bacteremia, received a
continuous infusion of vancomycin for at least 5 days, and
had a baseline serum creatinine < 1.5 mg/dL. Patients
were excluded if diagnosed with cystic fibrosis, bronchiec-
tasis, meningitis, or polymicrobial infection, if intravenous
contrast dye was given within 7 days of the start of vanco-
mycin treatment, and if data with regard to vancomycin
and creatinine serum levels were missing. The study was
approved by both Hospitals’ Institutional Review Boards.
In view of the retrospective and observational nature of
the study with no interventions performed, the need for
informed consent was waived.
A laboratory computed database was searched to iden-
tify all patients with community-, hospital-, or healthcare-
acquired pneumonia and bacteremia that had been treated
with continuous vancomycin infusion. For all patients, the
following information was retrieved from their medical
records: age, gender, weight, serial serum creatinine levels,
simplified acute physiology score (SAPS) 3, and daily van-
comycin plateau serum concentrations. Additionally, data
were collected on concomitant exposure to potential
nephrotoxic drugs (angiotensin converting enzyme inhibi-
tors (ACEi), angiotensin II receptor antagonists (AT-IIra),
nonsteroidal anti-inflammatory drugs (NSAIDs), amino-
glycosides and immunosuppressants (calcineurin inhibi-
tors (ciclosporin, tacrolimus) and sirolimus), and
underlying (diabetes) or acute (shock) risk factors for AKI.
Nephrotoxicity was defined by using the Acute Kidney
Injury Network (AKIN) classification [7] as an increase
in serum creatinine level of 0.3 mg/dL or a 1.5 to 2
times increase from baseline, whichever was greater,
(i.e., AKIN stage 1) on at least 2 consecutive days during
the period from initiation of vancomycin to 72 h after
completion of therapy. Urine output was not measured
as part of AKIN staging due to concerns about its
dependency on uncontrolled “extrarenal” events, such as
volume status, treatment with loop diuretics and vasoac-
tive agents, and release of antidiuretic hormone.
Nephrotoxic drug exposure was considered to be rele-
vant only when present during vancomycin infusion and
before increase in serum creatinine. Shock was defined
as the need for vasopressor therapy to obtain a mean
arterial pressure ≥70 mmHg in a patient who was ade-
quately fluid-resuscitated with crystalloid and colloid
solutions.
All patients received vancomycin as a 15-mg/kg loading
dose infused over 60 min, immediately followed by a con-
tinuous infusion of 30 mg/kg/day. Treatment was adjusted
afterwards based on plateau serum vancomycin concentra-
tions by increasing or decreasing the speed of the volu-
metric infusion device so that the daily dose was increased
or decreased by 500 mg [5]. Treatment was designed to
obtain a plateau vancomycin level between 15 and 25 μg/
mL. When vancomycin concentrations exceeded 30 μg/mL,
vancomycin infusion was interrupted for 6 h, after which
plasma concentrations were reevaluated. This procedure
was repeated until vancomycin levels returned within target
range. Vancomycin and creatinine levels were measured
daily at 8:00 A.M. in all patients. Vancomycin concentra-
tions were assessed by quantitative enzyme immunoassay
using the Vitros 5.1 FS Chemistry System (Ortho Clinical
Diagnostics, Inc., Beerse, Belgium) or the Dimension Vista
(Siemens Healthcare Diagnostics GmbH, Eschborn,
Germany) and classified in three groups: < 25 μg/mL,
25-30 μg/mL, and > 30 μg/mL.
Statistical analysis
Statistical measurements were performed by using SPSS
software, version 19.0 for Windows (SPSS, Inc., Chicago,
IL). Primary data analysis compared patients with AKI
with patients who did not develop AKI. Continuous vari-
ables were assessed with the Student’s t test for normally
distributed variables and the Mann-Whitney U test for
nonnormally distributed variables. The chi-square test
was used to compare categorical variables. Values were
expressed as means ± standard deviations (continuous
variables) or as a percentage of the group from which
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they were derived (categorical variables). P values were
two-tailed and considered to indicate statistical signifi-
cance at the < 0.05 level.
A binary logistic regression analysis using the for-
ward stepwise method with occurrence of AKI as
dependent variable was performed, including the fol-
lowing parameters: presence of diabetes or shock, use
of aminoglycosides, ACEi or AT-IIra, NSAIDs, and
immunosuppressants. All potentially explanatory vari-
ables in this regression were tested on multicollinearity
using the collinearity diagnostics by linear regression
calculating the variance inflation factor.
Results
During the study period, a total of 4,128 patients were
hospitalized in the ICUs of both hospitals. Of these, 129
patients with Gram-positive infection (MRSA (n = 82;
63.6%), methicillin-resistant coagulase-negative Staphylo-
cocci (n = 40; 31%), Enterococcus spp. (n = 7; 5.4%) were
selected for the study (Figure 1). Patients’ characteristics
are depicted in Table 1. Seventy-eight patients had pneu-
monia, 38 had bacteremia, and 13 had both pneumonia
and bacteremia. Thirty-eight subjects (29.5%) developed
AKI during vancomycin treatment. No relationship was
found between type of infection and incidence of AKI
(data not shown). Baseline creatinine values were com-
parable between patients with and without AKI (0.9 ±
0.19 mg/dL vs. 0.8 ± 0.35 mg/dL; p = 0.12). Age, gender,
and severity of illness also did not differ between patients
with and without AKI. Patients who developed AKI had a
higher lean body weight and were more likely to have
diabetes or shock. In both groups, a comparable number
of potential nephrotoxic agents were used concomitantly
with vancomycin. No association was found between this
nephrotoxic medication and the occurrence of AKI.
Patients with AKI received vancomycin for a more pro-
longed time period (14.9 ± 9.8 vs. 9.2 ± 4.9 days; p =
0.05). Creatinine concentrations in this group increased
after a mean duration of vancomycin treatment of 116 h
± 82 h (range, 53-402 h). Except for adjusting treatment
at levels > 30 μg/mL, vancomycin was never discontinued
or switched to an alternative agent. Mortality was higher
in patients who developed AKI (53% vs. 20%; p = 0.01).
The logistic regression multivariate analysis identified
vancomycin plasma level (p < 0.001), weight (p = 0.002),
and SAPS 3 (p = 0.024) as independent variables asso-
ciated with AKI. The probability of AKI can be calculated
as P = 1/1+ e-logit with logit = -6.54 + 0.055 × SAPS 3 +
0.067 × weight (kg) - 5.888 × 1 (if vancomycin level < 25
μg/mL) - 3.178 × 1 (if vancomycin level < 30 μg/mL). A
higher logit value results in an increased probability of
AKI. The highest logit is associated with vancomycin levels
exceeding 30 μg/mL and is further increased when SAPS 3
values or body weight rise. However, the three variables
differ in relative weight. Indeed, a 10 kg or 1 point increase
in respectively lean body weight or SAPS 3 will result in a
0.55 and 0.065 logit increase. In contrast, a vancomycin
level between 25 and 30 μg/mL causes a logit increase of
3.1718. Changes in the accuracy of the predictive model
also demonstrate the relative importance of the predicting
parameters. When the prediction model is based solely on
the vancomycin level, the addition of SAPS 3 as a marker
of disease severity and lean body weight causes only a very
modest increase of the overall percentage (from 86% to
86.8%) correctly predicted AKI. Including SAPS 3 in the
model containing vancomycin level and lean body weight
makes the Nagelkerke R2 increase from 0.637 to only
0.671. Adding any of the other observed variables to the
equation did not enhance predictive power. Testing for
potentially explanatory variables on multicollinearity
revealed a variance inflation factor between 1.097 and
1.56, thus far below 2.5, which is considered to be the
threshold value for concern of collinearity. The relation-
ship between the diabetes state and variables, such as age,
body weight, and SAPS 3, was closely examined, because it
seems reasonable to assume that diabetics are older, are
more overweight, and are likely to be more severely ill.
However, no significant correlation was identified. The
seeming paradox that diabetes and shock are found to be
associated with AKI in univariate analysis whilst multivari-
ate analysis demonstrated no contribution of these para-
meters to the accuracy of the model is due to differences
in methodology.
The distribution of vancomycin concentrations is shown
in Table 2. Within the group who developed AKI, a dis-
tinct association was found between vancomycin levels
and the occurrence of AKI (Figure 2). AKI was more fre-
quently found in patients with vancomycin levels between
25-30 μg/mL than in those with levels not exceeding
25 μg/mL (9 (24%) vs. 3 (8%) patients; odds ratio 9.75,
confidence interval 2.41-39.52; p < 0.0001). The incidence
of AKI sharply increased when vancomycin attained con-
centrations > 30 μg/mL compared with patients whose
values remained below this level (12 (32%) vs. 26 (68%)
patients; odds ratio 30.69, confidence interval 10.49-89.83;
p < 0.0001). No patient developed overt renal failure or
needed dialysis. Serum creatinine values at discharge had
returned to baseline levels in 12 of the 18 (66%) surviving
patients with vancomycin-associated AKI.
Discussion
Vancomycin is the first-line antibiotic treatment for
infections caused by MRSA and often is used for treat-
ment of other Gram-positive infections. Key factors that
determine appropriate dosing of vancomycin in MRSA
and staphylococcal bacteremia and pneumonia include
the MIC of the infecting organism and the risk of
nephrotoxicity. Pharmacological studies have determined
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that the parameter best predicting vancomycin activity is
the 24-h area under the concentration curve over the
MIC (AUC/MIC or AUIC). It is recommended that this
ratio be kept between 350 and 400 to achieve a good clin-
ical and microbiological response against MRSAs with
MIC values ≤1 μg/mL [8]. To determine vancomycin
effectiveness in the clinical setting, serum trough levels
are measured as a surrogate of AUIC. Aiming at high
trough concentrations will increase the likelihood of
achieving a more optimal AUIC but also the risk to
develop nephrotoxicity.
Several studies have evaluated the incidence of nephro-
toxicity–defined as a more than 50% increase of serum
creatinine from baseline value or an absolute increase of
serum creatinine of 0.5 mg/dL–during intermittent van-
comycin treatment. Two retrospective studies found that
when trough levels exceeded 10 μg/mL [9] or 15 μg/mL
[10], the incidence of nephrotoxicity increased by respec-
tively 17% and 27%. In a prospective cohort study that
included 80% patients with pneumonia or bacteremia,
Hidayat and coworkers observed 11.6% nephrotoxicity
when vancomycin dose was adjusted to achieve trough
Patients evaluated 
      n = 4128 
Patients not selected 
             n = 3999 
             no Gram-positive or polymicrobial 
             infection 
     n = 3925 
   
Gram-positive infection (*) 
                 n = 74 
- no pneumonia/bacteremia ; n = 18 
               - serum creatinine > 1.5 mg/dL ; n = 17 
               - neutrophils < 1000/μL ; n = 9 
               - vancomycin infusion < 5 days ; n = 31 
               - intravenous contrast ; n = 3 
- insufficient data ; n = 4 
Patients selected 
                  n = 129 
* more than 1 reason for exclusion possible 
Figure 1 Patient selection.
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values of four to five times the MIC of the infecting
MRSA strain [11]. These studies identified high vanco-
mycin trough levels, prolonged duration of vancomycin
therapy and ICU stay, and concomitant treatment with
nephrotoxic agents, in particular aminoglycosides, as
independent risk factors for nephrotoxicity. Our experi-
ence with continuous vancomycin infusion corroborates
these findings. Moreover, the risk to develop AKI in a
population consisting exclusively of critically ill ICU
patients was largely determined by conditions that signif-
icantly compromise the kidney, such as diabetes and
shock. Interestingly, we were unable to detect an associa-
tion between vancomycin-associated AKI and the use of
concomitant potentially nephrotoxic drugs. This could be
explained by standard “precautions” shared by both ICUs,
including short-term use of aminoglycosides under daily
monitoring of trough levels and a restrictive prescription
policy of NSAIDs and drugs acting on the renin-angio-
tensin pathway.
Continuous infusion of vancomycin has been proposed
as an elegant approach for maximizing efficacy of the drug
whilst avoiding development of resistance and adverse
renal effects. In clinical practice, a steady state plateau
plasma vancomycin concentration of 20-25 μg/mL is tar-
geted. This concentration is selected according to available
data on the drug’s tissue diffusion and protein binding
[12] and anticipates an eventual surreptitious MIC creep
[13]. Vancomycin levels are kept within target range by
therapeutic monitoring and dose adjustment according to
renal function. Using this approach, however, vancomycin
levels were found to be higher than 30 μg/mL in 24.8%
(32/129) of our study patients. A similar observation was
made by French investigators who reported trough vanco-
mycin serum levels that exceeded 30 μg/mL in 200 of 957
(20.9%) patients who received continuous infusion [14].
From the study by Wysocki and coworkers [5], it is appar-
ent that a substantial number of patients had steady state
vancomycin plasma levels > 25 μg/mL throughout contin-
uous treatment. These findings underscore that continu-
ous infusion aiming at plateau levels between 20 and 25
μg/mL may expose a significant proportion of patients to
higher than expected vancomycin concentrations, and
Table 1 Patient characteristics
Variable No AKI (n = 91) AKI (n = 38) P value
SAPS 3 67 ± 15 68 ± 14 0.63
Age, yrs 60.8 ± 14.6 62.6 ± 15.9 0.53
Weight, kg 70.5 ± 15.2 77.3 ± 15.0 0.02*
Gender, % male 51.6 60.5
Concomitant medication
Aminoglycosides, n (%) 39 (43) 12 (32) 0.32
ACEi or AT-IIra, n (%) 17 (19) 7 (18) 1
NSAIDs, n (%) 4 (4) 1 (3) 1
Immunosuppressants, n (%) 2 (2) 0 (0) 1
Comorbidities
Diabetes, n (%) 49 (54) 30 (79) 0.01*
Shock, n (%) 54 (59) 33 (87) 0.002*
AKI = acute kidney injury; SAPS = Simplified Acute Physiology Score; ACEi = angiotensin converting enzyme inhibitors; AT-IIra = angiotensin-II receptor
antagonists; NSAIDs = non steroidal anti-inflammatory drugs
* P level < 0,05 is considered significant
Table 2 Vancomycin levels in patients with and without
nephrotoxicity
Vancomycin concentration* (μg/mL) No AKI (n = 91) AKI (n = 38)
< 25 65 3
25-30 20 9
> 30 6 26
AKI = acute kidney injury,










< 25 25-30 > 30
% AKI
Vancomycin serum levels (μg/mL)
P < 0.0001
P < 0.0001
Figure 2 Vancomycin serum levels in patients who develop
acute kidney injury (AKI) during vancomycin infusion.
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hence nephrotoxicity. Ingram and coworkers indeed
detected a striking difference in incidence of nephrotoxi-
city at a vancomycin cutoff serum level of 28 μg/mL dur-
ing continuous infusion [15]. Above this level, 5 of 7
patients (71.4%) experienced a significant increase in
serum creatinine levels, whereas this occurred in only 11
of 91 patients (11.6%) whose vancomycin levels remained
below 28 μg/mL. This is in line with our observations that
indicated a substantial increase in AKI at vancomycin
levels between 25 and 30 μg/mL, which became alarming
when levels exceeded 30 μg/mL.
Although we cannot exclude that higher vancomycin
serum levels might reflect simple accumulation of the
drug, we believe that aiming at concentrations up to
25 μg/mL with continuous infusion is harming patients.
It may indicate that the actual algorithms to adapt vanco-
mycin dosing during continuous infusion should be
revised. Surprisingly, data on vancomycin dosing based
on solid pharmacodynamic studies in ICU patients are
scarce, in particular when renal function is decreasing.
Moreover, the proposed models present important draw-
backs. Information about infection type, severity of ill-
ness, resuscitation state, comorbid disease, and eventual
concomitant use of nephrotoxins is not provided [16,17].
Also, creatinine clearance is assessed by means of the
Cockroft-Gault formula, although it has been shown that
such estimation may poorly predict vancomycin clear-
ance in an ICU population [18]. Measurement of creati-
nine clearance or renal biomarkers (e.g., cystatin) may be
more practical and correct alternatives to determine van-
comycin dose requirements [18] but await prospective
validation.
Studies that compare continuous with intermittent
administration of vancomycin did not show a convincing
difference in occurrence of nephrotoxicity. Ingram and
coworkers retrospectively studied 167 patients with bone,
joint, and skin MRSA infection on an outpatient parent-
eral therapy with vancomycin [19]; 12 subjects were trea-
ted with continuous infusion and 55 received intermittent
vancomycin in an nonrandomized setting. Overall inci-
dence of nephrotoxicity was 15.6%. In 40 matched pairs of
patients, the incidence of nephrotoxicity when receiving
continuous or intermittent treatment was 10% versus 25%
(p = 0.14). Continuous infusion was associated with a
slower onset of nephrotoxicity. Vuagnat and coworkers
compared continuous with intermittent administration in
respectively 23 and 21 patients with osteomyelitis, aiming
at trough or plateau levels between 20 and 25 μg/mL [20].
Four (19%) patients undergoing intermittent treatment
but no patients undergoing continuous treatment devel-
oped nephrotoxicity. The largest prospective study on
continuous vancomycin treatment to date included 119
patients mostly suffering from pneumonia or bacteremia.
Sixty-one patients were randomized to receive continuous
infusion, aiming at plateau levels between 20 and 25 μg/
mL [5]. The remaining 58 subjects received vancomycin
intermittently to obtain trough levels between 10 and
15 μg/mL. Overall, a 20% incidence of nephrotoxicity was
observed without difference between continuous and
intermittent treatment (16.4% vs. 19%; p = 0.64).
Hutschala and coworkers retrospectively evaluated 149
patients who underwent cardiac surgery [21]. Depending
on ICU physicians’ preference, 119 patients were treated
with continuous infusion (target plateau 20-25 μg/mL)
and 30 patients received intermittent treatment (target
trough 15 μg/mL). Approximately 35% of patients in each
group had pneumonia or bacteremia. Nephrotoxicity was
defined according to the AKIN criteria. This study found
the highest incidence of nephrotoxicity (29.5%) but again
no difference between continuous and intermittent admin-
istration (27.7% vs. 36.7%; p = 0.3). Interestingly, we
observed nephrotoxicity in only 8% of patients whose van-
comycin levels remained between 15 and 25 μg/mL. This
is considerably lower than the 19% to 35% incidence of
nephrotoxicity reported at similar trough levels during
intermittent vancomycin administration [5,10,20,21].
It must be emphasized that attaining AKIN stage I, by
definition, does not signify renal failure. In fact, none of
our patients who developed vancomycin-associated renal
toxicity required renal replacement therapy (RRT) dur-
ing their ICU stay, nor was vancomycin discontinued or
replaced by alternative agents. Jeffres and coworkers
also reported no need for RRT in patients with severe
pneumonia who developed nephrotoxicity during inter-
mittent vancomycin treatment [10]. On the other hand,
Hutschala and coworkers reported the need for RRT in
25% of patients receiving continuous or intermittent
vancomycin treatment [21]. However, this study popula-
tion consisted of cardiac surgery patients at high risk for
developing postoperative acute renal failure with some
already presenting renal dysfunction at baseline. A
noticeable finding was that less patients under continu-
ous infusion required RRT after 5 days of vancomycin
treatment (23.5% vs. 30%, p = 0.053).
Some important limitations of our study deserve atten-
tion. We gave a vancomycin loading dose of 15 mg/kg
before starting continuous infusion. Recent clinical prac-
tice guidelines of the Infectious Diseases Society of
America (IDSA) recommend a loading dose of up to 25-
30 mg/kg to achieve target trough concentrations rapidly
in serious MRSA infections, including pneumonia and
bacteremia [22]. However, clinical and safety data regard-
ing this approach are lacking. Also, when we designed
the study, the IDSA guidelines had not yet been pub-
lished, and a 15-mg/kg loading dose was considered ade-
quate by most authors [5,16,17]. In this context, it is
important to note that the IDSA expert panel advises
against administration of vancomycin in continuous
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infusion given that a clear benefit over intermittent dos-
ing has not been demonstrated and because time above
the MIC is not the primary predictor of vancomycin effi-
cacy [22]. Although appropriate for large comparative
and epidemiological studies, the AKIN classification may
not be an accurate tool to assess a particular drug-related
nephrotoxic effect in critically ill patients, because a rise
in creatinine concentration occurs only after substantial
loss of renal function. A more appropriate way to corre-
late vancomycin serum levels with the occurrence of kid-
ney injury would have been to consider vancomycin
concentrations in the 48 h before the onset of AKI. How-
ever, it must be conceded that any rise in creatinine levels
will be delayed following “true” onset of AKI.
The retrospective nature of the study precluded the
use of creatinine clearance as a more optimal measure
of renal function and did not allow differentiation of
infection-related or AKI-induced mortality. For the
same reason, microbiological and clinical cure rates and
infection-related mortality were not evaluated. This
would require the identification of individual vancomy-
cin MIC values, because these are known to influence
significantly both treatment efficacy and mortality in
MRSA pneumonia [23] and bacteremia [2]. Finally, it is
conceivable that the higher vancomycin concentrations
may have identified these patients with a hidden or pro-
gressing renal failure rather than be the cause of a sub-
sequent increase in creatinine. Thus, the results of the
present study suggest a possible vancomycin exposure-
toxicity relationship but definite proof of causality will
require a blinded, prospective trial.
Conclusions
A frail balance exists between obtaining therapeutic
serum levels and avoiding nephrotoxicity during continu-
ous vancomycin infusion in critically ill patients with
severe Gram-positive infections and normal baseline
renal function. AKI is detected already at “conventional”
serum vancomycin plateau levels but peaks alarmingly at
values exceeding 30 μg/mL. AKI was not found to be
associated with the concomitant use of nephrotoxic med-
ication but is influenced rather by conditions that are
known to chronically worsen (diabetes) or acutely injure
(shock) renal function. Our study does not support the
concept that continuous infusion with vancomycin
reconciles optimization of vancomycin pharmacody-
namics against SA infections with less risk of
nephrotoxicity.
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